Title: NMDAR - glycine modulatory site as pharmacological target in depression: inhibition of glycine transporter I

**Abstract**

**Background:** Recently, modulation of glutamatergic neurotransmission has become an attractive approach for discovering novel antidepressants. Antagonists of the NMDA subtype glutamate receptor (NMDAR), such as ketamine, exhibit antidepressant-like effects in animal models and in patients with major depression and bipolar depression. On the other hand, decades ago, D-cycloserine, a partial agonist of the NMDAR, was incidentally found to have antidepressant activity. Lately, NMDA-enhancing treatments, such as sodium benzoate, also decreased depressive symptoms in patients with schizophrenia in clinical trials. Likewise, a reversible glycine transporter inhibitor, SSR504734, showed antidepressant effects in rodent models. In postmortem study, expression of NMDAR 1 and 2A subunit was decreased in brains of depressive patients. Therefore, hypofunction at the NMDAR may also play a role in major depression. However, it remains unclear whether enhancement of the NMDAR can be a treatment for depression.

**Methods:** We investigated the effects of sarcosine in various rodent models and conducted a 6-week randomized, double-blinded, citalopram-controlled trial in patients with major depressive disorder. Clinical efﬁcacy and safety were assessed biweekly.

**Results:** Sarcosine decreased immobility in the forced swim test and tail suspension test, and other depression-like behaviors in rats. For depression patients, sarcosine significantly ameliorated severity of depression and improved general function than citalopram treatment. Sarcosine-receivers were more likely to remit and stay at the study. Sarcosine had excellent safety profile.

**Discussion:** Our ﬁndings suggest that sarcosine can improve depression-like behaviors in rodent models and treat depression in humans. A recent study found that sarcosine, as ketamine, may exert its anti-depressive property by activating the mammalian target of rapamycin (mTOR) signaling pathway through stimulation of the AMPA receptor.
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